Hematologic Cancer
The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.
Oncology & Biotech News > Trials in Progress
Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.
Oncology & Biotech News > Conference Highlights
Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.
Conferences > 2012 Oncology Nursing Society Congress
William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.
Oncology Live > Features
Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.
Oncology & Biotech News > Conference Highlights
The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.
Oncology Live > Features
The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.
Oncology & Biotech News > Trials in Progress
Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients
with relapsed or refractory multiple myeloma.
Oncology Live > Conference Highlights
Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.
Oncology & Biotech News > Conference Highlights
ODAC voted 7-4 (2 abstentions) in support of vincristine sulfate liposomes injection to treat patients with Ph-negative ALL.
It may be possible to forgo radiation in previously untreated patients with limited-stage Hodgkin lymphoma.
Oncology & Biotech News > Conference Highlights
Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.
Oncology & Biotech News > Conference Highlights
Treatment of selected cases of localized lymphoma during the second and third trimester was associated with minimal maternal and fetal risk of complications.
Oncology & Biotech News > Conference Highlights
The burden of late complications after hematopoietic cell transplantation is high, and these late effects are associated with poor health and decreased functional status.
Oncology & Biotech News > Clinical Trial Reports
A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.
Oncology Live > Conference Highlights
A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.
Oncology & Biotech News > Conference Highlights
Certain characteristics of patients with CML can affect therapeutic outcomes.
Conferences > 2012 Hematologic Malignancies Congress
A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.
Conferences > 2012 Hematologic Malignancies Congress
Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS
Conferences > 2012 Hematologic Malignancies Congress
Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML
Conferences > 2012 Hematologic Malignancies Congress
External Resources
American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.